Triple tests Profile (3)
A focused veterinary chemistry panel in which the user selects 3 tests from 13 available analytes, allowing fast, lower-cost, question-driven screening on the Celercare V / Pointcare V platform.
What makes this panel different
This is a customizable 3-of-13 chemistry profile. It is designed for targeted decision-making when a full chemistry panel is unnecessary or when the clinician wants only the most relevant markers for the case.
Main clinical value
Useful for quick liver screening, renal triage, glucose or lipid checks, protein assessment, mineral screening, muscle injury support, and focused follow-up testing.
Platform workflow
Used with the Celercare V / Pointcare V chemistry analyzer with barcode-based calibration, 100 μL sample input, and either Type A or Type B disc workflow.
What this panel is for
The Triple tests Profile (3) is intended for in vitro quantitative determination of TP, ALB, ALT, ALP, TBIL, CRE, BUN, GLU, CHOL, CK, AMY, Ca, and P in heparinized whole blood, heparinized plasma, or serum. In clinical veterinary use, it supports investigation of hepatobiliary disease, urinary system disease, glucose metabolism and lipid metabolism disorders, pancreatic disease, and selected cardiovascular or muscle-related presentations.
Parameters
Available test items (13)
Calculation items
*These are only available when the required source analytes are included in the selected trio. Example: GLO and ALB/GLO require TP + ALB, BUN/CRE requires BUN + CRE, and Ca×P requires Ca + P.
Recommended 3-test combinations
Because this profile is customizable, choosing the right combination is the key to getting useful information from only three results. The best trio depends on the question you are trying to answer.
1) Quick liver injury and cholestasis screen
ALT + ALP + TBIL
Best when jaundice, vomiting, anorexia, hepatobiliary disease, gallbladder disease, or drug-associated liver concern is suspected. ALT supports hepatocellular injury, ALP supports cholestatic response, and TBIL adds bilirubin burden.
2) Protein pattern with liver context
TP + ALB + ALT
Useful in chronic disease, weight loss, edema, ascites, chronic enteropathy suspicion, or liver follow-up. This combination unlocks GLO and ALB/GLO while still adding a hepatocellular marker.
3) Liver protein balance and bilirubin check
TP + ALB + TBIL
Helpful when reduced hepatic synthetic support, chronic inflammation, protein-losing disease, or jaundice is part of the differential. Gives GLO and ALB/GLO and adds bilirubin burden.
4) Renal azotemia triage
BUN + CRE + P
Best when dehydration, renal compromise, urinary obstruction, or post-renal disease is suspected. This combination provides BUN/CRE and adds phosphorus to strengthen renal interpretation.
5) Renal plus metabolic emergency screen
BUN + CRE + GLU
Useful in acutely ill patients where both renal status and dysglycemia matter, including diabetic crises, severe dehydration, shock, or hospitalized follow-up. Provides BUN/CRE.
6) Pancreatic support screen
AMY + GLU + BUN
A practical low-cost combination when vomiting, abdominal pain, anorexia, or pancreatitis is suspected but a full panel is not being run. Amylase is supportive only, so clinical context remains essential.
7) Cholestatic / endocrine / lipid screen
CHOL + ALP + GLU
Useful for hyperlipidemia, cholestatic disease, endocrine screening, and metabolic follow-up. This trio often works well in diabetic, obese, or steroid-exposed patients.
8) Calcium–phosphorus balance
Ca + P + ALB
Best when mineral balance, renal mineral burden, nutritional issues, or hypercalcemia/hypocalcemia workup is the priority. Ca×P becomes available, and albumin helps interpret total calcium more intelligently.
9) Muscle injury with renal concern
CK + CRE + BUN
Helpful after trauma, seizures, exertional injury, or suspected rhabdomyolysis when you want to assess both muscle leakage and renal filtration support. Provides BUN/CRE.
Sample, workflow, and handling
Accepted specimen types
Lithium heparin whole blood, lithium heparin plasma, serum, or approved quality control material.
Sample volume
100 μL sample input per disc.
Type A / Type B workflow
Type A is the disc without diluent container and requires 430 μL sterilized water for injection. Type B includes the diluent container.
Timing
Whole blood collected by venipuncture should be mixed gently before transfer. Perform the test within 60 minutes and start analysis within 10 minutes after loading the sample to the disc.
Storage
Store sealed reagent discs at 2–8°C. Do not expose opened or unopened discs to direct sunlight or temperatures above 32°C. Do not use discs from damaged pouches.
Important handling note
Light can decompose TBIL, so samples not tested immediately should be protected from light. Use lithium heparin collection tubes for whole blood or plasma.
Interference and reporting cautions
The analyzer monitors for physiologic interferents such as hemolysis, lipemia, and icterus. Results affected by more than about 10% interference may be suppressed and reported as HEM, LIP, or ICT instead of a numeric result. Potassium is not part of this panel, but protein and phosphorus results can still be affected by specimen quality. Avoid hemolysis during collection, protect bilirubin from light, and do not rerun analyzer-out-of-range results by simple dilution unless the validated procedure specifically allows it.
How to read the selected analytes
Protein block
TP, ALB, GLO, and ALB/GLO help with hydration assessment, inflammation clues, oncotic support, hepatic synthetic support, and protein-losing conditions. A normal TP can still hide opposing albumin and globulin changes, so the pair matters more than TP alone.
Liver / biliary block
ALT is the main hepatocellular leakage enzyme in this profile. ALP supports cholestatic response and biliary disease patterns. TBIL adds bilirubin burden and can rise with cholestasis, hemolysis, or impaired hepatic handling.
Renal block
CRE, BUN, and BUN/CRE are the key renal components. Creatinine is generally the better filtration marker, while BUN is more affected by dehydration, diet, protein catabolism, and GI bleeding.
Pancreatic / metabolic block
AMY is a supportive pancreatic marker but is not fully specific for pancreatitis. GLU is essential in dysglycemia and critical illness. CHOL contributes to endocrine, cholestatic, and lipid metabolism assessment.
Muscle block
CK helps detect skeletal muscle injury, exertional damage, injections, trauma, or seizure-related leakage. Without AST in this profile, CK remains useful but should still be interpreted with history and exam.
Mineral block
Ca, P, and Ca×P help screen mineral balance, renal mineral consequences, nutritional issues, and soft tissue mineralization risk when both calcium and phosphorus are increased.
Quick high / low interpretation guide
| Analyte | Main intent of use | When high may suggest | When low may suggest / key notes |
|---|---|---|---|
| TP | Hydration and protein screening | Dehydration, hyperglobulinemia | Protein loss, hemorrhage, dilution; interpret with ALB and GLO |
| ALB | Oncotic support and protein loss/synthesis clue | Usually dehydration | Protein loss, reduced synthesis, dilution |
| ALT | Hepatocellular injury | Hepatocyte leakage/injury | Low values rarely matter clinically |
| ALP | Cholestatic response | Cholestasis, biliary disease, steroid or growth effects in some species | Low values usually not significant |
| TBIL | Bilirubin burden | Cholestasis, hemolysis, impaired hepatic handling | Protect from light; low values usually not significant |
| CRE | Filtration marker | Decreased GFR, renal/postrenal causes | May be lower with low muscle mass |
| BUN | Renal and protein metabolism marker | Dehydration, renal disease, GI bleeding, catabolism | Hepatic dysfunction, low protein intake, dilution |
| CK | Muscle injury support | Muscle trauma, injections, seizures, exertion | Low values usually not significant |
| AMY | Pancreatic support marker | Pancreatic disease support, renal retention, some GI disease | Low values rarely useful |
| GLU | Metabolic and emergency screening | Stress hyperglycemia, diabetes mellitus, endocrine disease | Sepsis, insulin excess, severe hepatic dysfunction, delayed separation artifact |
| CHOL | Lipid / cholestatic screening | Cholestasis, endocrine disease, nephrotic patterns | Malabsorption, shunting, severe hepatic dysfunction |
| Ca | Mineral balance | Hypercalcemia, renal/endocrine disease, neoplasia | Hypoalbuminemia or true hypocalcemia; total calcium is not ionized calcium |
| P | Renal and mineral burden marker | Reduced excretion, growth, cell breakdown, vitamin D issues | Losses, malnutrition/refeeding issues, endocrine causes |
| GLO* | Inflammatory/immune protein estimate | Inflammation, chronic antigenic stimulation, gammopathy | Low globulin states or protein loss |
| ALB/GLO* | Protein balance clue | Relative globulin depletion | Relative globulin excess or albumin loss |
| BUN/CRE* | Disproportion clue | BUN disproportionately high in dehydration, GI bleeding, catabolism | Lower ratio may fit low urea production or relatively higher creatinine |
| Ca×P* | Mineralization risk screen | Higher product increases concern for soft tissue mineralization risk | Context dependent; not a stand-alone diagnosis |
Panel-specific diagnostic scenarios
1) ALT high + ALP normal/mild + TBIL normal
More consistent with a primarily hepatocellular leakage pattern than marked cholestasis, though clinical context and trend monitoring still matter.
2) ALT mild + ALP high + TBIL high
More supportive of cholestatic or biliary disease than pure hepatocellular injury. Consider gallbladder or bile flow disorders.
3) TP low + ALB low
Raises concern for protein loss, hemorrhage, dilution, severe malnutrition, or reduced hepatic synthetic support depending on the case.
4) TP normal + ALB low
Often means globulins are relatively increased, which can happen with inflammation masking the albumin decrease.
5) BUN high + CRE high + P high
Strongly supports azotemia with possible renal contribution. Urinalysis and imaging are needed to separate prerenal, renal, and postrenal causes.
6) BUN high + CRE normal
More compatible with dehydration, GI bleeding, or protein catabolism than a pure filtration problem, though early renal change is still possible.
7) AMY high + GLU high
Can support a pancreatic/metabolic picture in the right patient, but amylase alone does not confirm pancreatitis and must be read with signs and imaging.
8) Ca high + P high
Raises concern for renal disease, vitamin D-related problems, or other mineral dysregulation. The Ca×P product becomes important for mineralization risk.
9) CK high + CRE rising
Supports muscle injury with possible secondary renal impact, especially in trauma, seizures, or severe exertional damage.
Guideline reference intervals from the product IFU
These ranges are provided by the manufacturer as a guideline only. Laboratories and clinics should establish or validate intervals for their own patient population and specimen type where possible.
| Analyte | Dog (SI) | Cat (SI) | Dog (Common) | Cat (Common) |
|---|---|---|---|---|
| TP | 52–82 g/L | 54–89 g/L | 5.2–8.2 g/dL | 5.4–8.9 g/dL |
| ALB | 22–44 g/L | 22–45 g/L | 2.2–4.4 g/dL | 2.2–4.5 g/dL |
| ALT | 10–118 U/L | 8.2–100 U/L | 10–118 U/L | 8.2–100 U/L |
| ALP | 20–150 U/L | 10–90 U/L | 20–150 U/L | 10–90 U/L |
| TBIL | 2–15 μmol/L | 2–15 μmol/L | 0.1–0.9 mg/dL | 0.1–0.9 mg/dL |
| CRE | 27–124 μmol/L | 27–186 μmol/L | 0.3–1.4 mg/dL | 0.3–2.1 mg/dL |
| BUN | 2.5–9.6 mmol/L | 3.6–12.9 mmol/L | 7–27 mg/dL | 10–36 mg/dL |
| GLU | 3.89–7.95 mmol/L | 4.11–8.84 mmol/L | 70–143 mg/dL | 74–159 mg/dL |
| CHOL | 2.84–8.26 mmol/L | 1.68–5.81 mmol/L | 110–320 mg/dL | 65–225 mg/dL |
| CK | 20–200 U/L | 50–450 U/L | 20–200 U/L | 50–450 U/L |
| AMY | 400–2500 U/L | 400–2500 U/L | 400–2500 U/L | 400–2500 U/L |
| Ca | 1.98–2.95 mmol/L | 1.95–2.95 mmol/L | 7.9–11.8 mg/dL | 7.8–11.8 mg/dL |
| P | 0.81–2.2 mmol/L | 1–2.74 mmol/L | 2.5–6.8 mg/dL | 3.1–8.5 mg/dL |
Analytical performance highlights
Dynamic ranges
| Analyte | Dynamic range |
|---|---|
| TP | 20–100 g/L |
| ALB | 10–60 g/L |
| TBIL | 2–550 μmol/L |
| ALP | 5–2000 U/L |
| ALT | 5–1500 U/L |
| BUN | 0.9–35.7 mmol/L |
| CRE | 20–2000 μmol/L |
| CK | 5–3000 U/L |
| GLU | 1–35 mmol/L |
| CHOL | 0.5–14 mmol/L |
| AMY | 5–3000 U/L |
| Ca | 0.5–4 mmol/L |
| P | 0.2–7 mmol/L |
Accuracy and precision snapshot
Manufacturer performance claims indicate allowable relative or absolute deviation limits of:
- ≤5% for Ca
- ≤6% for TP and ALB
- ≤10% for TBIL, ALP, CRE, CK, CHOL, AMY, and P
- ≤15% for ALT and BUN
- ≤20% for GLU
Reported batch precision ranges from about 2–8% CV depending on analyte, and inter-batch precision claims are generally ≤10%.
References
Primary product / IFU references
- Triple tests Profile (3) IFU
- Celercare V / Pointcare V chemistry analyzer operator’s manual
Veterinary interpretation references
Important interpretation note
Reference intervals vary by analyzer, species, specimen type, and laboratory population. Results should always be interpreted with history, physical examination, and—when clinically relevant—CBC, urinalysis, imaging, and repeat trends.